ALTO-300 not checked

Alto Neuroscience

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Major Depressive Disorder
Main trialPhase 2
“The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.”In the company’s words, NCT05922878 on ClinicalTrials.gov

Other drugs for Major Depressive Disorder

All 36 drugs for Major Depressive Disorder

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Dec 2026 Study of ALTO-300 in MDD
Phase 2Completed 26 Apr 2023 ALTO-300 in Depression (ALTO-300-004)
Phase 2Completed 5 May 2023 ALTO-300 in Depression
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ALTO-300

Following is part of Solo: you see every change to ALTO-300 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in